Christophe Pannecouque
Leuven, VLG 3000, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 280 publications
Targeted Degradation of Capsid by Host-Hijacking PROTAC Overcomes Drug Resistance.
Journal: Journal of medicinal chemistry
Published: July 13, 2026
Rational design of dual-site NNRTIs based on 2,4,5-trisubstituted pyrimidine scaffold for potent inhibition of resistant HIV-1.
Journal: European journal of medicinal chemistry
Published: June 15, 2026
Correction to "Rational Design of Broad-Spectrum Non-Nucleoside Reverse Transcriptase Inhibitors via Pharmacophore-Oriented Generative Artificial Intelligence".
Journal: Journal of medicinal chemistry
Published: April 20, 2026
Discovery of Potent 1,2,4-Triazole-Derived HIV Capsid Modulators with Dual-Stage Antiviral Activity via Targeting the Unexplored GTNQ Sub-Pocket Using a Multi-Site Binding Strategy.
Journal: Journal of medicinal chemistry
Published: April 02, 2026
Rational Design of Broad-Spectrum Non-Nucleoside Reverse Transcriptase Inhibitors via Pharmacophore-Oriented Generative Artificial Intelligence.
Journal: Journal of medicinal chemistry
Published: March 30, 2026
Surface Plasmon Resonance as a Potential Diagnostic Tool for the Detection of CXC Chemokine Receptor 4 (CXCR4) on Extracellular Vesicles.
Journal: Biosensors
Published: February 13, 2026
Cyclization-Inspired Structural Optimization: Designing Potent Non-nucleoside Reverse Transcriptase Inhibitors with Enhanced Safety and Selectivity.
Journal: Journal of medicinal chemistry
Published: January 09, 2026
Correction to "Exploring the HIV-1 Reverse Transcriptase p51/p66 Interface: Structure-Based Design and Optimization of Novel 2,4,6-Trisubstituted Pyrimidines as Potent NNRTIs with Improved Resistance Profiles".
Journal: Journal of medicinal chemistry
Published: October 23, 2025
Structure- and Privileged Fragment-Based Iterative Optimization: Discovery of 2,4-Disubstituted-6-aminopyrimidines as Novel HIV-1 NNRTIs with Potent Activity against Drug-Resistant Strains and Favorable Safety Profiles.
Journal: Journal of medicinal chemistry
Published: October 20, 2025
Discovery of novel diarylpyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors: Design, synthesis and biological activity evaluation.
Journal: Bioorganic chemistry
Published: October 18, 2025
Coumarin-stavudine (d4T) novel hybrid ProTides with dual-functionality and enhanced anti-HIV activity.
Journal: European journal of medicinal chemistry
Published: October 10, 2025
Exploring the HIV-1 Reverse Transcriptase p51/p66 Interface: Structure-Based Design and Optimization of Novel 2,4,6-Trisubstituted Pyrimidines as Potent NNRTIs with Improved Resistance Profiles.
Journal: Journal of medicinal chemistry
Published: September 17, 2025
Last Updated: 09/26/2026